1. .Bovenschen N, Herz J, Grimbergen JM & et al. Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency. Blood 2003; 101(10): 3933-9. [
DOI]
2. Iorio A, Stonebraker JS, Chambost H & et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med 2019; 171(8): 540-6. [
DOI]
3. Morange PE, Tregouet DA, Frere C & et al. Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. Br J Haematol. 2005; 128(1): 91-9. [
DOI]
4. Schambeck CM, Hinney K, Haubitz I & et al. Familial clustering of high factor VIII levels in patients with venous thromboembolism. Arterioscler Thromb Vasc Biol 2001; 21(2): 289-92. [
DOI]
5. Shen BW, Spiegel PC, Chang CH & et al. The tertiary structure and domain organization of coagulation factor VIII. Blood 2008; 111(3): 1240-7. [
DOI]
6. Salimi R, Zolfaghari B, Isfahani H & et al. Frequency of primary clinical manifestations of bleeding diseases in patients referred to Besat Hospital in Hamadanin 2020-2021. Sci J Iran Blood Transfus Organ 2022; 19(2): 122-130. [
Article]
7. Hazendonk HC, Lock J, Mathôt RA & et al. Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications. J Thromb Haemost 2016 Mar; 14(3): 468-78. [
DOI]
8. Franchini M, Coppola A, Santoro C & et al. ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients: A Study from the Italian Association of Hemophilia Centers. Semin Thromb Hemost 2021; 47(1): 84-89. [
DOI]
9. Ray D, Kumar N, Hans C & et al. Impact of ABO blood group antigens on residual factor VIII levels and risk of inhibitor development in hemophilia A. Blood res 2023; 58(1): 61-70. [
DOI]
10. Wu O, Bayoumi N, Vickers MA & et al. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008; 6(1): 62-9. [
DOI]
11. Lenting PJ, Christophe OD, Denis CV. Von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood 2015; 125(13): 2019- 28. [
DOI]
12. Martenez-Sanchez LM, Cardona-Velez J, RamirezPulgarin S & et al. Clinical and epidemiological profile of patients with hemophilia in Liga de Hemofilicos de Antioquia (Colombia). Revista Medica de Risaralda 2017; 23(1): 34-7. [
Article]
13. Sona PS, Lingam CM. Hemophilia-An overview. IJPSRR 2010; 5(1): 18-26. [
Article]
14. Bicocchi MP, Pasino M, Lanza T & et al. Analysis of 18 novel mutations in the factor VIII gene. Br J Haematol 2003; 122(5): 810-7. [
DOI]
15. Azimifar SB, Seyedna SY, Zeinali S. Allele frequencies of three factor VIII gene polymorphisms in Iranian populations and their application in hemophilia A carrier detection. Am J Hematol 2006; 81(5): 335-9. [
DOI]
16. Tuinenburg A, Mauser-Bunschoten EP, Verhaar MC & et al. Cardiovascular disease in patients with hemophilia. J Thromb Haemost 2009; 7(2): 247-54. [
DOI]